focus -WSS

focus

author：fashion 2025-09-06 04:15:17 - browse：54

The Food and Drug Administration is poised to tell drug and medical device makers how to better include people of color in the clinical trials that test whether products work and are safe, an agency official said Wednesday. Those guidelines are five months late.

To ensure that drugs work for everyone, they must be tested on a representative sample of people. But researchers have found that many clinical trials exclude the people of color who are often most affected by the diseases that drugs treat.

To help fix that problem, Congress passed a law requiring companies to give the FDA their plans for diversifying clinical trials. As part of that process, the agency was expected to issue guidance by the end of last year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Diversity in clinical trials starts with building trust, experts say

WSS

Public health communication lessons from Covid

Key Senate committee drafts bipartisan bill to stem drug shortages

Exact Sciences stock tumbles despite strong cancer detection sales

As the dark side of IVF slowly comes into focus, even more transparency is needed

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

Element Biosciences CEO lays out genome sequencing strategy

knowledge

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

hotspot

Supreme Court strikes down use of affirmative action

Bird flu outbreak in cows is latest avian flu curveball

Apple is now the first public company to be valued at $3 trillion

‘We were in the air.’ Mississippi family recounts surviving tornado that tore mobile home apart

DIEP, the 'gold standard' of breast reconstruction, is under threat

Element Biosciences CEO lays out genome sequencing strategy

Novavax promises a turnaround & Lilly roils the obesity market

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Behind warning on Apellis’s eye drug lies a conflict of interest

hotspot

Exact Sciences stock tumbles despite strong cancer detection sales

Bird flu in milk supply is likely coming from asymptomatic cows

‘We were in the air.’ Mississippi family recounts surviving tornado that tore mobile home apart

UnitedHealth financials solid despite Change Healthcare cyberattack

Ending health disparities requires full federal government, panel says

More tobacco lobbyists active in statehouses

focus

leisure time

Wikipedia

hotspot